SCHEMBL3885154

SCHEMBL3885154

CCn1ncc2cc(-c3cc(CCC(=O)O)ccc3OCc3ccc(C(F)(F)F)cc3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 5/20 0.45
FFAR1 O14842 4/20 0.44
FFAR2 O15552 1/20 0.44
S1PR1 P21453 3/20 0.43
PPARA Q07869 5/20 0.42
PPARD Q03181 4/20 0.42
PPARG P37231 2/20 0.42
S1PR3 Q99500 1/20 0.41
S1PR5 Q9H228 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
TP53 P04637 2/20 0.40
MDM2 Q00987 2/20 0.40
ALOX5 P09917 1/20 0.40
PSEN1 P49768 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884123 0.91 TP53 (0.49) FFAR4FFAR1TP53MDM2
SCHEMBL3882621 0.90 FFAR4 (0.46) FFAR4FFAR1FFAR2S1PR1PPARA
SCHEMBL3882459 0.90 FFAR4 (0.48) FFAR4FFAR1TP53MDM2
SCHEMBL3881517 0.89 TP53 (0.46) FFAR4FFAR1TP53MDM2
SCHEMBL3881740 0.86 TP53 (0.50) FFAR4FFAR1TP53MDM2
SCHEMBL3884482 0.85 PPARD (0.52) FFAR4FFAR1FFAR2PPARAPPARD
SCHEMBL3883493 0.84 NR1H2 (0.43) FFAR4S1PR1PPARAPPARDPPARG
SCHEMBL3884724 0.84 FFAR4 (0.45) FFAR4FFAR1S1PR1S1PR5TP53
SCHEMBL3881254 0.83 TP53 (0.51) FFAR4FFAR1PPARAPPARDPPARG
SCHEMBL3884144 0.83 S1PR1 (0.44) FFAR4S1PR1S1PR3S1PR5TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885FFAR1 13/4885FFAR2 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.